Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Windlas BiotechNSE:WINDLAS -0.14%90 ROC (Joel Greenblatt) % is 26.50% as of Mar. 2026, which is 11% below its 10-year median of 29.68. GuruFocus rates NSE:WINDLAS with a GF Score™ of 90/100 and a GF Value™ of ₹939.87 (Fairly Valued). The stock has 1 warning sign investors should review. Among 983 Drug Manufacturers companies, Windlas Biotech ranks better than 74.36% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Windlas Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 26.50%.
The historical rank and industry rank for Windlas Biotech's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:WINDLAS'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 16.94 Med: 29.68 Max: 95.16
Current: 30.33
During the past 8 years, Windlas Biotech's highest ROC (Joel Greenblatt) % was 95.16%. The lowest was 16.94%. And the median was 29.68%.
NSE:WINDLAS's ROC (Joel Greenblatt) % is ranked better than 74.36% of 983
companies
in the Drug Manufacturers industry
Industry Median: 11.46
vs NSE:WINDLAS: 30.33
Windlas Biotech's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 11.60% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Windlas Biotech ROC (Joel Greenblatt) % Related Terms
Windlas Biotech ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:WINDLAS vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 26.50% mean?
Windlas Biotech (NSE:WINDLAS) has a ROC (Joel Greenblatt) % of 26.50% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Windlas Biotech and its competitors. This is 11% below median its historical median of 29.68. Over the past decade, Windlas Biotech's ROC (Joel Greenblatt) % has ranged from 16.94 to 95.16. According to the industry distribution chart, Windlas Biotech ranks #252 out of 983 companies in the Drug Manufacturers industry, placing it in the top 25.6%.
Is Windlas Biotech's ROC (Joel Greenblatt) % too high?
Windlas Biotech's current ROC (Joel Greenblatt) % of 26.50% is 11% below median its 10-year median of 29.68. Over the past 10 years, this metric has ranged from a low of 16.94 to a high of 95.16. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.46. Windlas Biotech's value of 26.50% is 131.2% above this industry median. Based on the distribution chart, Windlas Biotech ranks #252 out of 983 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #252 out of 983 companies for ROC (Joel Greenblatt) %. This puts Windlas Biotech in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.46. Windlas Biotech's value of 26.50% is 131.2% above this benchmark. Historically, Windlas Biotech's own ROC (Joel Greenblatt) % has ranged from 16.94 to 95.16 over the past decade. While the company's 10-year median is 29.68 vs. the industry median of 11.46, Windlas Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current ROC (Joel Greenblatt) % of 26.50% is 131.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current ROC (Joel Greenblatt) % is 26.50%, which is 11% below median its own 10-year median of 29.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹939.87, compared to a current price of ₹851.05 — trading 9.5% below its estimated fair value. The current ROC (Joel Greenblatt) % is 26.50%, which is 11% below median its 10-year median of 29.68 and 131.2% above the Drug Manufacturers industry median of 11.46. Windlas Biotech's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current ROC (Joel Greenblatt) % is 26.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹851.05 is trading 9.5% below its estimated GF Value™ of ₹939.87.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
ROC (Joel Greenblatt) %: 26.50% (11% below median its 10-year median of 29.68)
GF Value™: ₹939.87 vs. price of ₹851.05 (9.5% below fair value)
Industry Position: 131.2% above the Drug Manufacturers median (#252 of 983)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
90GF Score
Get the complete analysis for NSE:WINDLAS
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
